The Janus face of pluripotent stem cells - Connection between pluripotency and tumourigenicity

BioEssays

Volumn 32, Issue 11, 2010, Pages 993-1002

  Wobus, Anna M ^a  

^a LEIBNIZ INSTITUTE OF PLANT GENETICS AND CROP PLANT RESEARCH IPK   (Germany)

Author keywords

Embryonic carcinoma cells; Embryonic stem cells; Induced pluripotent stem cells; P53; Pluripotency; Teratocarcinoma

Indexed keywords

PROTEIN P53; TELOMERASE;

ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; DOWN REGULATION; EMBRYONAL CARCINOMA; EMBRYONAL CARCINOMA STEM CELL; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENETIC MANIPULATION; GENOMIC INSTABILITY; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; SOMATIC CELL; TERATOCARCINOMA;

EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS; PLURIPOTENT STEM CELLS;

EID: 77958177490     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201000065     Document Type: Article

References (113)

1. Stevens LC, Little CC., 1954., Spontaneous testicular teratomas in an inbred strain of mice., Proc Natl Acad Sci USA, 40: 1080-97.
2. Stevens LC., 1970., The development of transplantable teratocarcinomas from intratesticular grafts of pre and postimplantation mouse embryos., Dev Biol, 21: 364-82.
3. Youngren KK, Coveney D, Peng X, Bhattacharya C, et al., 2005., The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours., Nature, 435: 360-4.
4. Ramalho-Santos M, Willenbring H., 2007., On the origin of the term "stem cell"., Cell Stem Cell, 1: 35--8.
5. Till JE, McCulloch EA., 1961., A direct measurement of the radiation sensitivity of normal mouse bone marrow cells., Radiat Res, 14: 213-22.
6. Kahan BW, Ephrussi B., 1970., Developmental potentialities of clonal in vitro cultures of mouse testicular teratoma., J Natl Cancer Inst, 44: 1015-29.
7. McBurney MW, Jones-Villeneuve EM, Edwards MK, Anderson PJ., 1982., Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line., Nature, 299: 165-7.
8. Solter D, Knowles B., 1978., Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1)., Proc Natl Acad Sci USA, 75: 5565-9.
9. Brinster RL., 1974., The effect of cells transferred into the mouse blastocyst on subsequent development., J Exp Med, 140: 1049-56.
10. Papaioannou VE, Gardner RL, McBurney MW, Babinet C, et al., 1978., Participation of cultured teratocarcinoma cells in mouse embryogenesis., J Embryol Exp Morphol, 44: 93-104.
11. Andrews PW., 2002., From teratocarcinomas to embryonic stem cells., Philos Trans R Soc Lond B, 357: 405-17.
12. Evans MJ, Kaufman MH., 1981., Establishment in culture of pluripotential cells from mouse embryos., Nature, 291: 154-6.
13. Martin G., 1981., Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells., Proc Natl Sci USA, 78: 7634-8.
14. Smith AG, Heath JK, Donaldson DD, Wong GG, et al., 1988., Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides., Nature, 336: 688-90.
15. Williams RL, Hilton DJ, Pease S, Wilson TA, et al., 1988., Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells., Nature, 336: 684-7.
16. Wobus AM, Boheler KR., 2005., Embryonic stem cells: Prospects for developmental biology and cell therapy., Physiol Rev, 85: 635-78.
17. Huebner K, Fuhrmann G, Christenson LK, Kehler J, et al., 2003., Derivation of oocytes from mouse embryonic stem cells., Science, 300: 1251-6.
18. Toyooka Y, Tsunekawa N, Akasu R, Noce T., 2003., Embryonic stem cells can form germ cells in vitro, Proc Natl Acad Sci USA, 200: 11457-62.
19. Bradley A, Evans M, Kaufman MH, Robertson E., 1984., Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines., Nature, 309: 255-6.
20. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, et al., 1993., Derivation of completely cell culture-derived mice from early-passage embryonic stem cells., Proc Natl Acad Sci USA, 90: 8424-8.
21. Eggan K, Akutsu H, Loring J, Jackson-Grusby L, et al., 2001., Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation., Proc Natl Acad Sci USA, 98: 6209-14.
22. Thomas KR, Capecchi MR., 1987., Site directed mutagenesis by gene targeting in mouse embryo-derived stem cells., Cell, 51: 503-12.
23. Thomson JA, Itskovits-Eldor J, Shapiro SS, Waknitz MA, et al., 1998., Embryonic stem cell lines derived from human blastocysts., Science, 282: 1145-7.
24. Murry C, Keller G., 2008., Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development., Cell, 132: 661-80.
25. Shamblot MJ, Axelman J, Wang S, Bugg EM, et al., 1998., Derivation of pluripotent stem cells from cultured human primordial germ cells., Proc Natl Acad Sci USA, 95: 13726-31.
26. Landry DW, Zucker HA., 2004., Embryonic death and the creation of human embryonic stem cells., J Clin Invest, 114: 1184-6.
27. Peura T, Bosman A, Chami O, Jansen RP, et al., 2008., Karyotypically normal and abnormal human embryonic stem cell lines derived from PGD-analyzed embryos., Cloning Stem Cells, 10: 203-16.
28. Zhang X, Stojkovic P, Przyborski S, Cooke M, et al., 2006., Derivation of human embryonic stem cells from developing and arrested embryos., Stem Cells, 24: 2669-76.
29. Chung Y, Klimanskaya I, Becker S, Li T, et al., 2008., Human embryonic stem cell lines generated without embryo destruction., Cell Stem Cell, 2: 113-7.
30. L-ser P, Schirm J, Guhr A, Wobus AM, et al., 2010., Human embryonic stem cell lines and their use in international research., Stem Cells, 28: 240-6.
31. Colman A, Dreesen O., 2009., Pluripotent stem cells and disease modeling., Cell Stem Cell, 5: 244-7.
32. Zwaka TP, Thomson JA., 2003., Homologous recombination in human embryonic stem cells., Nat Biotechnol, 3: 319-321.
33. Zou J, Cochran R, Cheng L., 2010., Double knockouts in human embryonic stem cells., Cell Res, 20: 250-2.
34. Ben-Nun IF, Benvenisty N., 2006., Human embryonic stem cells as a cellular model for human disorders., Mol Cell Endocrinol, 252: 154-9.
35. Zou J, Maeder ML, Mali P, Pruett-Miller SM, et al., 2009., Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells., Cell Stem Cell, 5: 97-110.
36. Schnerch A, Cerdan C, Bhatia M., 2010., Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and man., Stem Cells, 28: 419-30.
37. Tesar PJ, Chenoweth JG, Brook FA, Davies, et al., 2007., New cell lines from mouse epiblast share defining features with human embryonic stem cells., Nature, 448: 196-9.
38. Brons IG, Smithers LE, Trotter MW, Rugg-Gunn P, et al., 2007., Derivation of pluripotent epiblast stem cells from mammalian embryos., Nature, 448: 191-5.
39. Hanna J, Cheng AW, Saha K, Kin J, et al., 2010., Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs., Proc Natl Acad Sci USA., 107: 9222-7.
40. Takahashi K, Yamanaka S., 2006., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors., Cell, 126: 663-76.
41. Rossant J., 2009., Reprogramming to pluripotency: from frogs to stem cells., Cell, 138: 1047-50.
42. Wilmuth I, Schnieke AE, McWhir J, Kind AJ, et al., 1997., Viable offspring derived from fetal and adult mammalian cells., Nature, 385: 810-3.
43. Okita K, Ichisaka T, Yamanaka S., 2007., Generation of germline-competent induced pluripotent stem cells., Nature, 448: 313-7.
44. Wernig M, Meissner A, Foreman R, Brambrink T, et al., 2007., In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state., Nature, 448: 318-24.
45. Maherali N, Sridharan R, Xie W, Utikal J, et al., 2007., Directly reprogrammed fibroblasts show global epigenetic remodelling in widespread tissue contribution., Cell Stem Cell, 1: 55-70.
46. Takahashi K, Tanabe K, Ohnuki M, Narita M, et al., 2007., Induction of pluripotent stem cells from adult human fibroblasts by defined factors., Cell, 131: 861-72.
47. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, et al., 2007., Induced pluripotent stem cell lines derived from human somatic cells., Science, 318: 1917-20.
48. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K., 2008., Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse., Cell Stem Cell, 2: 230-40.
49. Amabile G, Meissner A., 2009., Induced pluripotent stem cells: current progress and potential for regenerative medicine., Trends Mol Med, 15: 59-68.
50. Zhao X, Li W, Lv Z, Liu L, et al., 2009., iPS cells produce viable mice through tetraploid complementation., Nature, 461: 86-90.
51. Kang L, Wang J, Zhang Y, Kou Z, et al., 2009., iPS cells can support full term development of tetraploid blastocyst-complementation embryos., Cell Stem Cell, 5: 135-8.
52. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, et al., 2009., Adult mice generated from induced pluripotent stem cells., Nature, 461: 91-4.
53. Soldner F, Hockemeyer D, Beard C, Gao Q, et al., 2009., Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors., Cell, 136: 964-77.
54. Kaji K, Norrby K, Paca A, Mileikovsky M, et al., 2009., Virus-free induction of pluripotency and subsequent excision of reprogramming factors., Nature, 458: 771-5.
55. Woltjen K, Michael IP, Mohseni P, Desai R, et al., 2009., Piggyback transposition reprograms fibroblasts to induced pluripotent stem cells., Nature, 458: 766-70.
56. Zhou H, Wu S, Joo JY, Zhu S, et al., 2009., Generation of induced pluripotent stem cells using recombinant proteins., Cell Stem Cell, 4: 381-4.
57. Kim D, Kim CH, Moon JI, Chung YG, et al., 2009., Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins., Cell Stem Cell, 4: 472-6.
58. Huangfu D, Osafune K, Maehr R, Guo W, et al., 2008., Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2., Nat Biotechnol, 26: 1269-75.
59. Shi Y, Do JT, Desponts C, Hahm HS, et al., 2008., A combined chemical and genetic approach for the generation of induced pluripotent stem cells., Cell Stem Cell, 2: 525-8.
60. Seifinejad A, Tabebordbar M, Baharvand H, Boyer LA, et al., 2010., Progress and promise towards safe induced pluripotent stem cells for therapy., Stem Cell Rev Rep, DOI: 10.1007/s12015-010-9121-x.
61. Ebert AD, Svendsen CN., 2010., Human stem cells and drug screening: Opportunities and challenges., Nat Rev Drug Disc, 9: 367-70.
62. Park IH, Arora N, Huo H, Maherali N, et al., 2008., Disease-specific induced pluripotent stem cells., Cell, 134: 877-88.
63. Ebert AD, Yu J, Rose FF, Mattis VB, et al., 2009., Induced pluripotent stem cells from a spinal muscular atrophy patient., Nature, 457: 277-80.
64. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, et al., 2008., Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons., Science, 321: 1218-21.
65. Saha K, Jaenisch R., 2009., Technical challenges in using human induced pluripotent stem cells to model diseases., Cell Stem Cell, 5: 584-95.
66. Caspi O, Itzhaki I, Arbel G, Kehat I, et al., 2008., In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes., Stem Cells Dev, 18: 161-72.
67. Egli D, Birkhoff G, Eggan K., 2008., Mediators of reprogramming: transcription factors and transitions through mitosis., Nat Rev Mol Cell Biol, 9: 505-16.
68. Jalving M, Schepers H., 2009., Induced pluripotent stem cells: will they be safe?, Curr Opin Mol Ther, 11: 383-93.
69. Chin MH, Mason MJ, Xie W, Volinia S, et al., 2009., Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures., Cell Stem Cell, 5: 111-23.
70. Feng Q, Lu SJ, Klimanskaya I, Gomes I, et al., 2010., Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence., Stem Cells, 28: 704-12.
71. Hu B-Y, Weick JP, Yu J, Ma L-X, et al., 2010., Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency., Proc Natl Acad Sci USA, 107: 4335-40.
72. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, et al., 2010., Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells., Nature, 465: 175-81.
73. Knoepfler PS., 2009., Deconstructing stem cell tumourigenicity: a roadmap to safe regenerative medicine., Stem Cells, 27: 1050-6.
74. Dreesen O, Brivanlou AH., 2007., Signaling pathways in cancer and embryonic stem cells., Stem Cell Rev, 3: 7-17.
75. Krizhanowsky V, Lowe SW., 2009., Stem cells. The promises and perils of p53., Nature, 460: 1085-6.
76. Gidekel S, Pizov G, Bergman Y, Pikarsky E., 2003., Oct3/4 is a dose-dependent oncogenic fate determinant., Cancer Cell, 4: 361-70.
77. Schoenhals M, Kassambara A, De Vos J, Hose D, et al., 2009., Embryonic stem cell markers expression in cancers., Biochem Biophys Res Commun, 383: 157-62.
78. Rowland BD, Bernards R, Peeper DS., 2005., The Klf4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene., Nat Cell Biol, 7: 1074-82.
79. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, et al., 2008., Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts., Nat Biotechnol, 26: 101-6.
80. Viswanathan SR, Daley GQ., 2010., Lin28: a microRNA regulator with a macro role., Cell, 140: 445-9.
81. Zhao T, Xu Y., 2010., p53 and stem cells: new developments and new concerns., Trends Cell Biol, 20: 170-5.
82. Cervantes RB, Stringer JR, Shao C, Tischfield JA, et al., 2002., Embryonic stem cells and somatic cells differ in mutation frequency and type., Proc Natl Acad Sci USA, 99: 3586-90.
83. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, et al., 1998., ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage., Curr Biol, 8: 145-55.
84. Chambers I, Smith A., 2004., Self-renewal of teratocarcinoma and embryonic stem cells., Oncogene, 23: 7150-60.
85. Kawamura T, Suzuki J, Wang Y, Menendez S, et al., 2009., Linking the p53 tumour suppressor pathway to somatic cell reprogramming., Nature, 460: 1140-4.
86. Li H, Collado M, Villasante A, Strati K, et al., 2009., The Ink/Arf locus is a barrier for iPS cell reprogramming., Nature, 460: 1136-9.
87. Hong H, Takahashi K, Ichisaka T, Aoi T, et al., 2009., Suppression of induced pluripotent stem cell generation by the p53-p21 pathway., Nature, 460: 1132-5.
88. Marion RM, Strati K, Li H, Murga M, et al., 2009b, A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity., Nature, 460: 1149-53.
89. Eliyahu D, Raz A, Gruss P, Givol D, et al., 1984., Participation of p53 cellular tumour antigen in transformation of normal embryonic cells., Nature, 312: 646-9.
90. Blackburn EH., 2001., Switching and signaling at the telomere., Cell, 106: 661-73.
91. Marion RM, Strati K, Li H, Tejera A, et al., 2009., Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells., Cell Stem Cell, 4: 141-54.
92. Vaziri H, Chapman KB, Guigova A, Teichroeb J, et al., 2010., Spontaneous reversal of the developmental aging of normal human cells following transcriptional reprogramming., Regen Med, 5: 345-63.
93. Zalzman M, Falco G, Sharova LV, Nishiyama A, et al., 2010., Zscan4 regulates telomere elongation and genomic stability in ES cells., Nature, 464: 858-63.
94. Baker DEC, Harrison NJ, Maltby E, Smith K, et al., 2007., Adaptation to culture of human embryonic stem cells and oncogenesis in vivo., Nat Biotechnol, 25: 207-15.
95. Blum B, Benvenisty N., 2008., The tumorigenicity of human embryonic stem cells., Adv Cancer Res, 100: 133-58.
96. Longo L, Bygrave A, Grosveld FG, Pandolfi PP., 1997., The chromosome make-up of mouse embryonic stem cells is predictive of somatic and germ cell chimaerism., Transgenic Res, 6: 321-8.
97. Draper JS, Smith K, Gokhale P, Moore HD, et al., 2004., Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells., Nat Biotechnol, 22: 53-4.
98. Maitra A, Arkin DA, Shivapurkar N, Ikeda M, et al., 2005., Genomic alterations in cultured human embryonic stem cells., Nat Genet, 37: 1099-103.
99. Weikert S, Schrader M, Krause H, Schulze W, et al., 2005., The inhibitor of apoptosis (IAP) survivin is expressed in human testicular germ cell tumors and normal testes., Cancer Lett, 223: 331-7.
100. Hammond S, Zhu R, Youngren KK, Lam J, et al., 2007., Chromosome X modulates incidence of testicular germ cell tumors in Ter mice., Mamm Genome, 18: 832--8.
101. Herszfeld D, Wolvetang E, Langton-Bunker E, Chung TL, et al., 2006., CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells., Nat Biotechnol, 24: 351-7.
102. Närwä E, Autio R, Rahkonen N, Kong L, et al., 2010., High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity., Nat Biotechnol, 28: 371-7.
103. Allegrucci C, Wu YZ, Thurston A, Denning CN, et al., 2007., Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome., Hum Mol Genet, 16: 1253-68.
104. Hentze H, Graichen R, Coleman A., 2007., Cell therapy and the safety of embryonic stem cell-derived grafts., Trends Biotechnol, 25: 24-32.
105. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, et al., 2009., Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient., PLoS Med, 6: 1000029.
106. Graf T, Enver T., 2009., Forcing cells to change lineages., Nature, 462: 587-94.
107. Gurdon JB, Melton DA., 2008., Nuclear reprogramming in cells., Science, 322: 1811-15.
108. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, et al., 2010., Direct conversion of fibroblasts to functional neurons by defined factors., Nature, 463: 1035-41.
109. Xie H, Ye M, Feng R, Graf T., 2004., Stepwise reprogramming of B cells into macrophages., Cell, 117: 663-76.
110. Zhou Q, Brown J, Kanarek A, Rajagopal J, et al., 2008., In vivo reprogramming of adult pancreatic exocrine cells to β-cells., Nature, 455: 627-32.
111. Takeuchi JK, Bruneau BG., 2009., Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors., Nature, 459: 708-11.
112. Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, et al., 1989., Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD., Proc Natl Acad Sci USA, 86: 5434-8.
113. Blau H, Chiu CP, Pavlath GK, Webster C., 1985., Muscle gene expression in heterokaryons., Adv Exp Med Biol, 182: 231-47.